473 related articles for article (PubMed ID: 7707120)
1. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.
Greco FA; Figlin R; York M; Einhorn L; Schilsky R; Marshall EM; Buys SS; Froimtchuk MJ; Schuller J; Schuchter L; Buyse M; Ritter L; Man A; Yap AK
J Clin Oncol; 1996 Oct; 14(10):2674-81. PubMed ID: 8874326
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
Seymour MT; Slevin ML; Kerr DJ; Cunningham D; James RD; Ledermann JA; Perren TJ; McAdam WA; Harper PG; Neoptolemos JP; Nicholson M; Duffy AM; Stephens RJ; Stenning SP; Taylor I
J Clin Oncol; 1996 Aug; 14(8):2280-8. PubMed ID: 8708718
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
5. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y
Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869
[TBL] [Abstract][Full Text] [Related]
8. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Köhne CH; Wilke H; Hecker H; Schöffski P; Käufer C; Rauschecker H; Andreesen R; Ohl U; Lange HJ; Klaassen U
Ann Oncol; 1995 May; 6(5):461-6. PubMed ID: 7669711
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Hausmaninger H; Moser R; Samonigg H; Mlineritsch B; Schmidt H; Pecherstorfer M; Fridrik M; Kopf C; Nitsche D; Kaider A; Ludwig H
Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286
[TBL] [Abstract][Full Text] [Related]
11. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Scheithauer W; Kornek G; Marczell A; Salem G; Karner J; Kovats E; Burger D; Greiner R; Pidlich J; Schneeweiss B; Raderer M; Rosen H; Depisch D
J Clin Oncol; 1997 Mar; 15(3):908-14. PubMed ID: 9060527
[TBL] [Abstract][Full Text] [Related]
12. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Papavramidis S; Bousoulegas A; Basdanis G; Giannoulis E; Dokmetzioglou J; Katsohis C; Nenopoulou E; Karvounis N; Briassoulis E; Aravantinos G; Kosmidis P; Skarlos D; Pavlidis N
Oncology; 2000 Apr; 58(3):227-36. PubMed ID: 10765125
[TBL] [Abstract][Full Text] [Related]
13. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Jäger E; Heike M; Bernhard H; Klein O; Bernhard G; Lautz D; Michaelis J; Meyer zum Büschenfelde KH; Knuth A
J Clin Oncol; 1996 Aug; 14(8):2274-9. PubMed ID: 8708717
[TBL] [Abstract][Full Text] [Related]
14. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R
J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
Buter J; Sinnige HA; Sleijfer DT; de Vries EG; Willemse PH; van der Graaf WT; Verschueren RC; Mulder NH
Cancer; 1995 Mar; 75(5):1072-6. PubMed ID: 7850703
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
20. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
Hill M; Norman A; Cunningham D; Findlay M; Watson M; Nicolson V; Webb A; Middleton G; Ahmed F; Hickish T
J Clin Oncol; 1995 Sep; 13(9):2317-23. PubMed ID: 7666089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
